Novartis: OmalizumabAchieved all Targets in Phase III Safety Registration

Novartis: OmalizumabAchieved all Targets in Phase III Safety Registration

An announcement made by the Swiss drugmaker Novartis AG (NVS: Quote) on Wednesday suggested about the late-breaking results omalizumab clearing all the primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria or CSU.

It is a chronic and debilitating form of hives with partial approved treatment options. GLACIAL is considered as the second of three pivotal Phase III studies. These studies conduct analysis about the efficacy and safety of omalizumab in CSU.

The result derived from the study supported supported the efficacy, safety and tolerability of omalizumab in patients with refractory CSU. It is a kind of chronic and debilitating skin disease with obstinate itch and hives.

Near about 40 percent of CSU patients were unsuccessful on ntihistamines. These include those who were taking the approved dose even for the fourth time. The doses, in terms of official regulations are currently available only for treatment for CSU.

However, Omalizumab is presently not at all approved or indicated for CSU. Supervision of the submissions for omalizumab in CSU is scheduled for later times in the current year. It is a collaborated effort of Novartis and Genentech, Inc.

The data was brought forward for the first time at the European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress 2013 in Milan which is located in Italy.


FrenchTribune Specials

Windows 10 Anniversary Update will add two advanced security capabilities

The forthcoming Anniversary Update of Microsoft Woindows10 OS will bring along the addition of several new features, including advanced security capabilities which will enable IT managers to more effectively lock down the computers in their organization.

The two new advanced security capabilities which are being added to Windows 10 OS as...

Exxon reports 46% decline in First Quarter earning

On Thursday, Exxon reported a 46% decline in earnings in the first quarter, by earning $4.9 billion compared with $9.1 billion in the same quarter a year ago. Exxon's top and bottom lines declined due to lower oil prices.

It was the...

Most Popular

Study finds no link between IVF and risk of breast cancer

A new study claimed that women who undergo in-vitro...

Nvidia unveils its latest flagship graphics card --- Titan X

Chip maker Nvidia has unveiled its newest flagship...

Nail biting and thumb-sucking might be healthy for children

To all those parents who have tough time in making their...

Facebook Messenger app grows to more than 1 billion users

On Wednesday, social network Facebook announced that its...

Poll

Can Greece Come out of Economic Problems: